Mwanzo9VC • ETR
add
ATAI Life Sciences NV
Bei iliyotangulia
€ 1.21
Bei za siku
€ 1.22 - € 1.27
Bei za mwaka
€ 0.93 - € 2.50
Thamani ya kampuni katika soko
291.51M USD
Wastani wa hisa zilizouzwa
elfu 1.60
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | elfu -5.00 | -127.78% |
Matumizi ya uendeshaji wa biashara | 29.34M | -12.62% |
Mapato halisi | -38.96M | -112.98% |
Kiwango cha faida halisi | elfu 779.16 | 866.72% |
Mapato kwa kila hisa | -0.24 | -100.00% |
EBITDA | -29.12M | 12.97% |
Asilimia ya kodi ya mapato | 1.81% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 62.33M | -65.23% |
Jumla ya mali | 159.39M | -45.69% |
Jumla ya dhima | 42.83M | -12.87% |
Jumla ya hisa | 116.55M | — |
hisa zilizosalia | 198.31M | — |
Uwiano wa bei na thamani | 1.75 | — |
Faida inayotokana na mali | -41.11% | — |
Faida inayotokana mtaji | -46.44% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -38.96M | -112.98% |
Pesa kutokana na shughuli | -24.30M | -10.62% |
Pesa kutokana na uwekezaji | 6.56M | 897.08% |
Pesa kutokana na ufadhili | elfu 154.00 | 101.82% |
Mabadiliko halisi ya pesa taslimu | -17.46M | 44.50% |
Mtiririko huru wa pesa | -1.72M | 86.74% |
Kuhusu
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2018
Tovuti
Wafanyakazi
54
